A study to test different doses of BI 1823911 alone and combined with other medicines in people with different types of advanced cancer with KRAS mutation.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512805-18-00

Acronym

1472-0001

Enrollment

Registered

2024-06-25

Start date

2021-08-03

Completion date

2025-10-22

Last updated

2025-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

solid tumour harbouring G12C mutation

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026